Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365991 | 0.94 | DDAH1 (0.41) | DDAH1CA1CA2TSHRALDH1A1 | |
| SCHEMBL6983472 | 0.87 | SLC1A1 (0.39) | DDAH1CA1CA2ZDHHC7LTA4H | |
| SCHEMBL8348754 | 0.87 | SLC1A1 (0.39) | DDAH1CA1CA2ZDHHC7LTA4H | |
| SCHEMBL23419880 | 0.87 | SLC1A1 (0.39) | DDAH1CA1CA2ZDHHC7LTA4H | |
| SCHEMBL9383516 | 0.87 | CA1 (0.43) | DDAH1CA1CA2ZDHHC7LTA4H | |
| SCHEMBL16330498 | 0.87 | ZDHHC7 (0.45) | DDAH1CA1CA2TSHRZDHHC7 | |
| Hydrochloric Acid SCHEMBL29262795 | 0.85 | SLC1A1 (0.38) | DDAH1CA1CA2ALDH1A1ZDHHC7 | |
| Hydrochloric Acid SCHEMBL29262798 | 0.85 | SLC1A1 (0.38) | DDAH1CA1CA2ALDH1A1ZDHHC7 | |
| Hydrochloric Acid SCHEMBL9383511 | 0.85 | CA1 (0.42) | DDAH1CA1CA2ALDH1A1ZDHHC7 | |
| Hydrochloric Acid SCHEMBL3623148 | 0.85 | CA1 (0.42) | DDAH1CA1CA2ALDH1A1ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2016-10-13 | — | — | US | disclosed |
| US-9187524-B2 | Broad spectrum antibiotic arylomycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-12 | — | — | US | disclosed |
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | THE SCIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2013138187-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2012036907-A2 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | ROMESBERG FLOYD E (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | DDAH1 2586/4885CA1 4844/4885CA2 4718/4885 |
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | DDAH1 2586/4885CA1 4844/4885CA2 4718/4885 |
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | DDAH1 2586/4885CA1 4844/4885CA2 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.